Metabolomic signature for the diagnosis of acute mesenteric ischemia
AssigneesAphp (Assistance Publique - HôPitaux De Paris), Université Paris Cité, Inserm (Institut National De La Sante Et De La Recherche Medicale), Imperial College of Science, Technology and Medicine
InventorsYoram BOUHNIK, Alexandre NUZZO, Olivier CORCOS, Marc-Emmanuel DUMAS, Antonis MYRIDAKIS, Dominique GAUGUIER
Life of this patent
Estimating the term…
Abstract
A metabolomic signature of acute mesenteric ischemia (AMI) and the determination thereof in a method for identifying a subject suffering or being at risk of suffering from AMI. Also, a kit that includes elements for determining the metabolomic signature of AMI and implementing the method for identifying a subject suffering or being at risk of suffering from AMI.
Claims17
1-15. (canceled)
A method for providing an adapted care to a subject identified as suffering or being at risk of suffering from acute mesenteric ischemia (AMI), said method comprising:
- a) determining a metabolomic signature of the subject by measuring in a biological sample previously obtained from the subject the level, amount, or concentration of at least one biomarker selected from the group consisting of isomaltose, glutamine, phenylalanine, glycerol, L1PN, 1-monoolein, L1AB, L3TG, threose, H4A2, L1TG, TPA2, and L1PL;
- b) comparing the metabolomic signature of the subject to a reference metabolomic signature;
- and
- c) providing an adapted care to the subject identified as suffering or being at risk of suffering from AMI based on the comparison of his/her metabolomic signature to the reference metabolomic signature.
A method for identifying a subject suffering or being at risk of suffering from acute mesenteric ischemia (AMI), said method comprising:
- a) determining a metabolomic signature of the subject by measuring in a biological sample previously obtained from the subject the level, amount, or concentration of at least one biomarker selected from the group consisting of isomaltose, glutamine, phenylalanine, glycerol, L1PN, 1-monoolein, L1AB, L3TG, threose, H4A2, L1TG, TPA2, and L1PL;
- b) comparing the metabolomic signature of the subject to a reference metabolomic signature;
- and
- c) identifying the subject suffering or being at risk of suffering from AMI based on the comparison of his/her metabolomic signature to the reference metabolomic signature.
A metabolomic signature of acute mesenteric ischemia (AMI), said metabolomic signature comprising at least one biomarker selected from the group consisting of isomaltose, glutamine, phenylalanine, glycerol, L1PN, 1-monoolein, L1AB, L3TG, threose, H4A2, L1TG, TPA2, and L1PL.
Dependencies are inferred from the claim text.